title: Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.
abstract: Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal and heart transplant recipients, was used in combination with cyclosporin A (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute graft-versus-host disease (aGVHD) after bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen (HLA)-mismatched, unrelated (n = 9) and related donors (n = 4) in an open single-centre phase II study. Thirteen patients, transplanted from HLA-mismatched donors of 18-57 yr of age, received 1 g MMF daily, starting at day 10, in addition to CsA and prednisolone for aGVHD prophylaxis. All patients were engrafted between days 13 and 15. Four of the 13 patients experienced aGVHD grade I/II (n = 2) and grade III (n = 2). All patients except 3 were alive on day 100 post-transplantation. No severe adverse effects of MMF were recorded. In our pilot study, we demonstrated that MMF can be used safely for the prophylaxis of aGVHD.
authors.affiliation: Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany. office@bmt-center-io.com
authors.forename: N
authors.initials: N
authors.lastname: Basara
authors.forename: W I
authors.initials: WI
authors.lastname: Blau
authors.forename: M G
authors.initials: MG
authors.lastname: Kiehl
authors.forename: B
authors.initials: B
authors.lastname: Schmetzer
authors.forename: M
authors.initials: M
authors.lastname: Bischoff
authors.forename: D
authors.initials: D
authors.lastname: Kirsten
authors.forename: S
authors.initials: S
authors.lastname: Günzelmann
authors.forename: A A
authors.initials: AA
authors.lastname: Fauser
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000276:immunology; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006680:HLA Antigens / Q000032:analysis*; D018380:Hematopoietic Stem Cell Transplantation; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010865:Pilot Projects; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012449:Safety; D015996:Survival Rate; D014019:Tissue Donors
chemical_list: D004338:Drug Combinations; D005938:Glucocorticoids; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D009173:Mycophenolic Acid; D008727:Methotrexate